Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972863 | 0.91 | USP2 (0.52) | USP2LMNAHTTHSD17B10AGTR1 | |
| SCHEMBL15119548 | 0.86 | MAPT (0.43) | USP2MAPTLMNATP53TSHR | |
| SCHEMBL17154471 | 0.85 | USP2 (0.47) | USP2MAPTLMNAHTTHSD17B10 | |
| SCHEMBL9972873 | 0.81 | HSD17B10 (0.47) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL9972862 | 0.81 | USP2 (0.43) | USP2LMNAHSD17B10AGTR1CYP1A2 | |
| SCHEMBL4249632 | 0.79 | USP2 (0.52) | USP2MAPTLMNAHTTHSD17B10 | |
| SCHEMBL13303943 | 0.77 | MAPT (0.50) | MAPTLMNATP53TSHRHTT | |
| Hydrochloric Acid SCHEMBL9583920 | 0.76 | LMNA (0.52) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL18560978 | 0.73 | HSD17B10 (0.41) | USP2MAPTLMNAHTTHSD17B10 | |
| SCHEMBL24615028 | 0.72 | USP2 (0.58) | USP2LMNATSHRHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | ACTELION PHARMACEUTICALS, LTD. (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8501818-B2 | Stabilized compositions of alkylating agents and methods of using same | CEPTARIS THERAPEUTICS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20100152300-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | HELSINN HEALTHCARE SA (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | USP2 1995/4885MAPT 1744/4885LMNA 2387/4885 |
| US-20100152300-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | USP2 1431/4885MAPT 2619/4885LMNA 2236/4885 |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | MGMT, UNG, OGG1 | USP2 1487/4885MAPT 3685/4885LMNA 2267/4885 |
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | USP2 1431/4885MAPT 2619/4885LMNA 2236/4885 |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | USP2 1995/4885MAPT 1744/4885LMNA 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.